Boehringer Ingelheim Breakfast Symposium: Prioritising Renoprotection in Diabetes: SGLT2i, GLP-1 RA or combination therapy?.
| Friday, August 22, 2025 |
| 7:15 AM - 8:15 AM |
| Room 6 |
Details
The landscape of diabetic kidney disease (DKD) management has evolved dramatically with the emergence of sodium glucose co-transporter inhibitors (SGLT2i) and GLP-1 receptor agonists (RAs), both demonstrating renoprotective and cardiometabolic benefits beyond glycaemic control. While SGLT2i have rapidly gained favour due to robust data supporting reductions in progression of kidney disease and heart failure hospitalisations, GLP-1 RAs offer compelling evidence for cardiovascular risk reduction and potential renal benefit, particularly in patients with high atherosclerotic burden. As guidelines increasingly advocate for their use, the question remains: which class should be prioritised as first-line therapy for renoprotection in DKD? This session will critically appraise the latest trial evidence, mechanistic insights, and practical considerations – Including patient selection, tolerability, and sequencing. Attendees will gain a nuanced understanding of each therapeutic class and be better equipped to make informed, individualised decisions in clinical practice. Join us for a dynamic and evidence-driven discussion on a key issue in contemporary diabetes care.
Speaker
Professor Bobby Chacko
Director of Renal Services
John Hunter Hospital
Prioritising Renoprotection in Diabetes: SGLT2i, GLP-1 RA or combination therapy?
Biography
Professor Chacko is the Director of Renal Services, and Senior Staff Specialist, Nephrology and Transplantation at John Hunter Hospital and holds an academic appointment at the University of Newcastle, Australia as Professor of Medicine. His expertise spans diabetic kidney disease, IgA nephropathy, hypertension, cardio-renal syndrome, and renal transplantation. He serves as the National Scientific Leader for clinical trials in IgA nephropathy and diabetic kidney disease and is a widely published researcher.
Prof Sophia Zoungas
Head, School of Public Health and Preventive Medicine
Monash University
Prioritising Renoprotection in Diabetes: SGLT2i, GLP-1 RA or combination therapy?
Biography
Professor Sophia Zoungas is the Head of the School of Public Health and Preventive Medicine, Monash University, a Professor of Diabetes, Vascular Health and Ageing, and the Academic Director of the Monash University Clinical Trials Centre. She is also a consultant Endocrinologist and Physician with clinical appointments at both Monash Health, including the Victorian Heart Hospital, and Alfred Health, Melbourne.
Professor Zoungas is internationally recognised for her expertise in the design and conduct of large multicentre, multinational clinical trials and cohort studies which have impacted directly on public health and clinical care. She has assembled international and national teams in diabetes, cardiovascular and kidney health, including investigator lead projects and large-scale clinical trials. Her significant contribution to the advancement of diabetes research has been recognised through the Kellion Diabetes Award and induction into the Australian Academy of Health and Medical Sciences.
Professor Zoungas has over 330 publications in peer-reviewed journals, including the New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Nature Reviews and she is recognised as one of the most cited researchers in the field of diabetes.
